ReviewClinical ophthalmology (Auckland, N.Z.)2015
Targeting interleukin-6 for noninfectious uveitis.
Review in Clinical ophthalmology (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Emerging therapeutic targets in non-infectious uveitis and scleritis.Frontiers in medicine · 2026Review
- Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial.The journal of allergy and clinical immunology. Global · 2025Article
- Tocilizumab for Non-Infectious Uveitis: A Systematic Review.Journal of inflammation research · 2025Review
- Effect of intravitreal injection of anti-interleukin (IL)-6 antibody in experimental autoimmune uveitis in mice.Journal of ophthalmic inflammation and infection · 2024Article
- Article
- Shaping the Future of Behçet's Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies.Ophthalmology and therapy · 2023Review
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- Long-acting acid-sensitive ketal-linked dexamethasone microcrystals for treating experimental autoimmune uveitis.APL bioengineering · 2022Article
- Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide.Scientific reports · 2022Article
- New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- The signal pathways and treatment of cytokine storm in COVID-19.Signal transduction and targeted therapy · 2021Review
- Acute oral treatment with resveratrol and Lactococcus Lactis Subsp. Lactis decrease body weight and improve liver proinflammatory markers in C57BL/6 mice.Molecular biology reports · 2021Article
- Epigenetic Modifications and Therapy in Uveitis.Frontiers in cell and developmental biology · 2021Review
- Recent advances in the management of non-infectious posterior uveitis.International ophthalmology · 2020Review
- MicroRNAs and Autoimmune-Mediated Eye Diseases.Frontiers in cell and developmental biology · 2020Review
- Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.International journal of ophthalmology · 2020Article
- Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.Journal of ophthalmic inflammation and infection · 2019Review
- Psoriasis and uveitis: links and risks.Psoriasis (Auckland, N.Z.) · 2019Article
- The associations between interleukin 10 polymorphisms and susceptibility to autoimmune uveitis - a meta-analysis.Central-European journal of immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Behçet disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.